Search
Reslizumab
go.drugbank.com/drugs/DB06602ApprovedInvestigationalReslizumab is marketed as Cinqaero in Europe. … In addition, a significant improvement in lung function was seen, as measured by the volume of air exhaled by patients in one second [L1133].
Cetyl alcohol
go.drugbank.com/drugs/DB09494ApprovedIt may be contained in cosmetic and personal care products such as shampoos, creams and lotions. … Due to its water-binding property, cetyl alcohol is commonly used as an emollient that prevents drying and chapping of the skin [A32209].
Ibalizumab
go.drugbank.com/drugs/DB12698ApprovedInvestigationalIt has been developed by Taimed biologics and Theratechnologies [L1558, L1554]. This drug was approved in March 2018 for the management of treatment-resistant HIV [L1554]. … Ibalizumab (also known as _ibalizumab-uiyk_ and formerly known as TNX-355) is a monoclonal antibody that binds to CD4 receptors on the surface of CD4-positive cells, preventing HIV particle entry into
Atoltivimab
go.drugbank.com/drugs/DB15898ApprovedInvestigationalINMAZEB™ is produced by Regeneron Pharmaceuticals and was granted FDA approval on October 14, 2020.[L17320] … [A222078] INMAZEB™, formerly referred to as REGN-EB3, combines the three humanized IgG1κ mAbs Atoltivimab (REGN 3470), [Odesivimab] (REGN 3471), and [Maftivimab] (REGN 3479) in equimolar proportions
Pasireotide
go.drugbank.com/drugs/DB06663ApprovedInvestigationalIt is marketed as a diaspartate salt called Signifor, which is used in the treatment of Cushing's disease.
Cobimetinib
go.drugbank.com/drugs/DB05239ApprovedInvestigationalIt has been approved in Switzerland and the US, in combination with vemurafenib for the treatment of patients with unresectable or metastatic BRAF V600 mutation-positive melanoma. … Cobimetinib is an orally active, potent and highly selective small molecule inhibiting mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), and central components of the RAS/RAF/MEK/ERK signal transduction
Panobinostat
go.drugbank.com/drugs/DB06603ApprovedInvestigationalPanobinostat acts as a non-selective histone deacetylase inhibitor (pan-HDAC inhibitor) and it is the most potent DAC inhibiting agent available on the market. … The approval was accelerated based on progression-free survival, therefore confirmatory trials by the sponsor to demonstrate clinical efficacy in multiple myeloma treatment are in progress of being conducted
Streptomycin
go.drugbank.com/drugs/DB01082ApprovedInvestigationalVet approved[A233325,A232294] Although streptomycin was the first antibiotic determined to be effective against mycobacterium tuberculosis, it has fallen out of favor due to resistance and is now primarily used as … Streptomycin, an antibiotic derived from _Streptomyces griseus_, was the first aminoglycoside to be discovered and used in practice in the 1940s.
Lanreotide
go.drugbank.com/drugs/DB06791ApprovedInvestigationalLanreotide is manufactured by the company, _Ipsen Pharmaceuticals_ as lanreotide acetate, and marketed as _Somatuline_. … Lanreotide was first approved for use in the United States by the FDA on August 30, 2007.
Abatacept
go.drugbank.com/drugs/DB01281ApprovedInvestigationalThe drug has activity as a selective co-stimulation modulator with inhibitory activity on T lymphocytes. … Although approved for the treatment of rheumatoid arthritis, Repligen has entered a slightly different formulation of CTLA4-Ig into clinical trials (RG2077).